The significance of pre-therapeutic F-18-FDG PET–CT in lymphoma-associated hemophagocytic lymphohistiocytosis when pathological evidence is unavailable

Journal of Cancer Research and Clinical Oncology

Volumn 142, Issue 4, 2016, Pages 859-871

  Wang, Jujuan ^a   Wang, Dongjiao ^a   Zhang, Qingbo ^a   Duan, Limin ^a   Tian, Tian ^a   Zhang, Xiaoyan ^a   Li, Jianyong ^a   Qiu, Hongxia ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Differential diagnosis; Lymphoma associated hemophagocytic lymphohistiocytosis (LAHLH); PET CT; Prognosis

Indexed keywords

ASPARAGINASE; BETA 2 MICROGLOBULIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IFOSFAMIDE; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; MESNA; MITOXANTRONE; PREDNISOLONE; VINCRISTINE; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BONE LESION; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SCREENING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORTICOSTEROID THERAPY; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEMOPHAGOCYTIC SYNDROME; HODGKIN DISEASE; HUMAN; IMAGE ANALYSIS; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LYMPHADENOPATHY; LYMPHOMA ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PET-CT SCANNER; PRIORITY JOURNAL; T CELL LYMPHOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION; COMPLICATION; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; LYMPHOMA; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; LYMPHOMA; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDNISONE; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VINCRISTINE;

EID: 84961159406     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-2094-z     Document Type: Article

References (40)

1. Ahn JS et al (2010) Clinical significance of clonality and Epstein-Barr virus infection in adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol 85:719–722
2. Chung TW (2007) CNS involvement in hemophagocytic lymphohistiocytosis: CT and MR findings. Korean J Radiol 8:78–81
3. Cronin CG et al (2010) Clinical utility of PET/CT in lymphoma. Am J Roentgenol 194:W91–W103
4. de Jong PA, van Ufford HMQ, Baarslag H-J, de Haas MJ, Wittebol SH, Quekel LG, de Klerk JM (2009) CT and 18F-FDG PET for noninvasive detection of splenic involvement in patients with malignant lymphoma. Am J Roentgenol 192:745–753
5. Emmenegger U, Schaer D, Larroche C, Neftel K (2005) Haemophagocytic syndromes in adults: current concepts and challenges ahead. Swiss Med Wkly 135:299–314
6. Farquhar JW, Claireaux AE (1952) Familial haemophagocytic reticulosis. Arch Dis Child 27:519
7. Filipovich AH (2009) Hemophagocytic lymphohistiocytosis (HLH) and related disorders. ASH Educ Program Book 2009:127–131
8. Fitzgerald NE, MacClain KL (2003) Imaging characteristics of hemophagocytic lymphohistiocytosis. Pediatr Radiol 33:392–401
9. Group HLS (2004) Treatment protocol of the second international HLH study. HLH 1:1–27
10. Gutierrez M et al (2000) Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 18:3633–3642
11. Henter JI et al (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48:124–131
12. Henzan T, Nagafuji K, Tsukamoto H, Miyamoto T, Gondo H, Imashuku S, Harada M (2006) Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am J Hematol 81:59–61
13. Hutchings M et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52–59
14. Imashuku S et al (1999) Effective control of Epstein-Barr virus—related hemophagocytic lymphohistiocytosis with immunochemotherapy. Blood 93:1869–1874
15. Imashuku S et al (2001) Requirement for etoposide in the treatment of Epstein-Barr virus—associated hemophagocytic lymphohistiocytosis. J Clin Oncol 19:2665–2673
16. Inoue K, Goto R, Okada K, Kinomura S, Fukuda H (2009) A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity. Ann Nucl Med 23:643–649
17. Janka G, Imashuku S, Elinder G, Schneider M, Henter J-I (1998) Infection-and malignancy-associated hemophagocytic syndromes: secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin N Am 12:435–444
18. Kaito K et al (1997) Prognostic factors of hemophagocytic syndrome in adults: analysis of 34 cases. Eur J Haematol 59:247–253
19. Kim J, Yoo SW, Kang S-R, Bom H-S, Song H-C, Min J-J (2013) Clinical implication of F-18 FDG PET/CT in patients with secondary hemophagocytic lymphohistiocytosis. Ann Hematol 1–7
20. Kleynberg RL, Schiller GJ (2012) Secondary hemophagocytic lymphohistiocytosis in adults: an update on diagnosis and therapy. Clin Adv Hematol Oncol 10:726–732
21. Larroche C et al (2000) [Intravenously administered gamma-globulins in reactive hemaphagocytic syndrome. Multicenter study to assess their importance, by the immunoglobulins group of experts of CEDIT of the AP-HP]. In: Annales de medecine interne, pp 533–539
22. Li F et al (2014) Identification of clinical features of lymphoma-associated hemophagocytic syndrome (LAHS): an analysis of 69 patients with hemophagocytic syndrome from a single-center in central region of China. Med Oncol 31:1–7
23. Liu Y (2009) Clinical significance of diffusely increased splenic uptake on FDG-PET. Nucl Med Commun 30:763–769
24. Lustberg MB, Aras O, Meisenberg BR (2008) FDG PET/CT findings in acute adult mononucleosis mimicking malignant lymphoma. Eur J Haematol 81:154–156
25. Mikhaeel N, Hutchings M, Fields P, O’Doherty M, Timothy A (2005) FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16:1514–1523
26. Ohga S, Matsuzaki A, Nishizaki M, Nagashima T, Kai T, Suda M, Ueda K (1993) Inflammatory cytokines in virus-associated hemophagocytic syndrome: interferon-gamma as a sensitive indicator of disease activity. J Pediatr Hematol Oncol 15:291–298
27. Olin RL, Nichols KE, Naghashpour M, Wasik M, Shelly B, Stadtmauer EA, Vogl DT (2008) Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. Am J Hematol 83:747–749
28. Park H-S et al (2012) Clinical features of adult patients with secondary hemophagocytic lymphohistiocytosis from causes other than lymphoma: an analysis of treatment outcome and prognostic factors. Ann Hematol 91:897–904
29. Pfreundschuh M et al (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9:105–116. doi:10.1016/S1470-2045(08)70002-0
30. Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, Khamashta MA, Bosch X (2014) Adult haemophagocytic syndrome. Lancet 383:1503–1516. doi:10.1016/S0140-6736(13)61048-X
31. Sheehy N, Israel DA (2007) Acute varicella infection mimics recurrent Hodgkin’s disease on F-18 FDG PET/CT. Clin Nucl Med 32:820–821
32. Shin H-J et al (2008) Treatment outcomes with CHOP chemotherapy in adult patients with hemophagocytic lymphohistiocytosis. J Korean Med Sci 23:439–444
33. Suga K, Kawakami Y, Hiyama A, Matsunaga N, Imoto S, Fukuda N, Miyazaki M (2010) F-18 FDG PET/CT findings in a case of T-cell lymphoma-associated hemophagocytic syndrome with liver involvement. Clin Nucl Med 35:116–120
34. Szyper-Kravitz M (2009) The hemophagocytic syndrome/macrophage activation syndrome: a final common pathway of a cytokine storm. Isr Med Assoc J 11:633–634
35. Thomas DA et al (2004) Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 104:1624–1630. doi:10.1182/blood-2003-12-4428
36. Tomas M, Tronco G, Karayalcin G, Palestro C (2000) 22. FDG uptake in infectious mononucleosis. Clin Positron Imaging 3:176
37. Tothova Z, Berliner N (2014) Hemophagocytic syndrome and critical illness: new insights into diagnosis and management. J Intensive Care Med. doi:10.1177/0885066613517076
38. Weiler-Sagie M et al (2010) 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 51:25–30
39. Wilson WH et al (2008) Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 26:2717–2724. doi:10.1200/JCO.2007.13.1391
40. Zhang L-J, Xu J, Liu P, Ding C-Y, Li J-Y, Qiu H-X, Zhang S-J (2012) The significance of 18F-FDG PET/CT in secondary hemophagocytic lymphohistiocytosis. J Hematol Oncol 5:40